Melissa Anne Mallory1, Karissa Whiting2, Anna Park1, Mithat Gönen2, Elizabeth Gilbert1, Tari A King3,4, Melissa L Pilewskie5. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 4. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 5. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer, 300 East 66th Street, New York, NY, 10065, USA. pilewskm@mskcc.org.
Abstract
PURPOSE: Lobular carcinoma in situ (LCIS) confers increased cancer risk in either breast, but it remains unclear if this population is at increased risk for bilateral breast cancer (BC) development. Here we report bilateral BC incidence among women with a history of LCIS. METHODS: Women with classic-type LCIS diagnosed from 1980 to 2017 who developed unilateral BC (UBC) or bilateral BC were identified. Bilateral BC was categorized as synchronous (bilateral BC diagnosed < 6 months apart; SBBC) or metachronous (bilateral BC diagnosed ≥ 6 months apart; MBBC). Five-year incidence rates of bilateral BC among this population were evaluated. Comparisons were made to identify factors associated with bilateral BC. RESULTS: At 7 years' median follow-up, 249/1651 (15%) women with LCIS developed BC; 34 with bilateral BC (2%). There were no clinicopathologic feature differences between those with UBC and bilateral BC. SBBC occurred in 18 without significant differences versus UBC. Among 211 with UBC and a contralateral breast at risk, 16 developed MBBC at a median follow-up of 3 years. MBBC patients were less likely to receive endocrine therapy and more likely to receive chemotherapy versus UBC. Tumor histology was not associated with MBBC. Estimated 5-year MBBC risk was 6.4%. Index estrogen/progesterone receptor positivity and endocrine therapy were the only factors associated with MBBC risk. CONCLUSION: Bilateral BC occurred in 2% of women with LCIS history at median follow-up of 7 years. Similar to the general BC population, a decrease in MBBC is seen among women with a history of LCIS who develop hormone receptor-positive disease and those who receive endocrine therapy, highlighting the protective effects of this treatment.
PURPOSE: Lobular carcinoma in situ (LCIS) confers increased cancer risk in either breast, but it remains unclear if this population is at increased risk for bilateral breast cancer (BC) development. Here we report bilateral BC incidence among women with a history of LCIS. METHODS: Women with classic-type LCIS diagnosed from 1980 to 2017 who developed unilateral BC (UBC) or bilateral BC were identified. Bilateral BC was categorized as synchronous (bilateral BC diagnosed < 6 months apart; SBBC) or metachronous (bilateral BC diagnosed ≥ 6 months apart; MBBC). Five-year incidence rates of bilateral BC among this population were evaluated. Comparisons were made to identify factors associated with bilateral BC. RESULTS: At 7 years' median follow-up, 249/1651 (15%) women with LCIS developed BC; 34 with bilateral BC (2%). There were no clinicopathologic feature differences between those with UBC and bilateral BC. SBBC occurred in 18 without significant differences versus UBC. Among 211 with UBC and a contralateral breast at risk, 16 developed MBBC at a median follow-up of 3 years. MBBC patients were less likely to receive endocrine therapy and more likely to receive chemotherapy versus UBC. Tumor histology was not associated with MBBC. Estimated 5-year MBBC risk was 6.4%. Index estrogen/progesterone receptor positivity and endocrine therapy were the only factors associated with MBBC risk. CONCLUSION: Bilateral BC occurred in 2% of women with LCIS history at median follow-up of 7 years. Similar to the general BC population, a decrease in MBBC is seen among women with a history of LCIS who develop hormone receptor-positive disease and those who receive endocrine therapy, highlighting the protective effects of this treatment.
Keywords:
Bilateral breast cancer; Breast cancer; Breast surgery; Contralateral breast cancer; Hormone receptor-positive disease; Lobular carcinoma in situ
Authors: Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: E Shelley Hwang; Sarah J Nyante; Yunn Yi Chen; Dan Moore; Sandy DeVries; James E Korkola; Laura J Esserman; Frederic M Waldman Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: Victor P Andrade; Irina Ostrovnaya; Venkatraman E Seshan; Mary Morrogh; Dilip Giri; Narciso Olvera; Marina De Brot; Monica Morrow; Colin B Begg; Tari A King Journal: Breast Cancer Res Date: 2012-07-09 Impact factor: 6.466